They concluded that HHP-Exo preferentially targets the heart and improves the therapeutic effect of CDC-Exos on cardiac hypertrophy, and that this therapeutic effect is likely due to miR-148a-mediated inhibition of GP130 and inhibition of the STAT3/ERK1/2/AKT signaling pathway, resulting in improved cardiac function and myocardial hypertrophy [132]. This evidence concerns the gene MAPK3 and cardiac hypertrophy.